Core Viewpoint - Sino Medical achieved a significant stock price increase of 19.99% on August 18, reaching a price of 41.48 CNY per share, with a trading volume of 2.032 billion CNY and a turnover rate of 12.37%, resulting in a total market capitalization of 17.258 billion CNY [1] Company Overview - Sino Medical Technology Co., Ltd. is located in the Tianjin Economic-Technological Development Area and specializes in the research, production, and sales of high-end interventional medical devices [1] - The company’s main products include coronary drug-eluting stents, coronary balloons, intracranial rapid exchange balloons, and intracranial drug-eluting stents, with over 1.4 million units used globally, serving hundreds of thousands of patients [1] - Sino Medical holds 8 key technologies, has launched 19 products, and possesses over 200 global patents, while undertaking 7 national and provincial scientific research projects [1] - Clinical research results of its products have been published in 31 articles in core domestic and international journals [1] Financial Performance - For the period from January to March 2025, Sino Medical reported a revenue of 101 million CNY, representing a year-on-year growth of 10.75% [1] - The net profit attributable to shareholders was 2.9693 million CNY, showing a substantial year-on-year increase of 277.50% [1] - As of March 31, the number of shareholders was 11,000, with an average of 37,400 circulating shares per person [1]

8月13日，赛诺医疗盘中19.99%涨停，截至14:19，报30.13元/股，成交30.05亿元，换手率26.34%，总市 值125.36亿元。 资料显示，赛诺医疗科学技术股份有限公司位于天津开发区第四大街5号泰达生物医药研发大厦B区2 层，公司是一家专注于高端介入医疗器械研发、生产、销售的国际化公司，主营产品包括冠脉药物支 架、冠脉球囊、颅内快速交换球囊、颅内药物洗脱支架等，累计使用超过140万个，服务于全球数十万 患者。公司拥有8项关键技术，已上市产品19款，全球专利数200余件，承担国家级、省级科研项目7 项，产品临床研究结果已在国内国际核心期刊发表31篇。 截至3月31日，赛诺医疗股东户数1.1万，人均流通股3.74万股。 2025年1月-3月，赛诺医疗实现营业收入1.01亿元，同比增长10.75%；归属净利润296.93万元，同比增长 277.50%。 来源：金融界 ...